Whole-Genome Sequencing and Disability in the NICU: Exploring Practical and Ethical Challenges

Area of Science:

• Medical Genetics
• Bioethics
• Disability Studies

Background:

• Clinical whole-genome sequencing (WGS) is increasingly used in neonatal intensive care units (NICUs) for rapid diagnosis and improved care management.
• Concerns exist from disability rights advocates regarding potential stigmatization and discrimination against disabled individuals due to genetic technologies.
• There is a critical need to examine how WGS in newborns might amplify existing social harms.

Purpose of the Study:

• To explore how clinical WGS in the neonatal period may exacerbate harms to persons with disabilities.
• To extend existing concerns about genetic technologies to the specific context of neonatal WGS.
• To encourage proactive ethical reflection among clinicians and bioethicists.

Main Methods:

• Literature review and ethical analysis of WGS in neonatal care.
• Consideration of perspectives from disability rights advocates.
• Exploration of potential social harms and mitigation strategies.

Main Results:

• Clinical WGS in the NICU, while beneficial for diagnosis, carries risks of reinforcing stigma and discrimination against disabled individuals.
• Failure to address these concerns could lead to significant social harms for individuals with disabilities and their families.
• Proactive ethical engagement is necessary to mitigate these risks.

Conclusions:

• Clinicians and bioethicists must consider the ethical implications of WGS in neonatal care, particularly regarding disability rights.
• Addressing concerns raised by disability advocates is essential for fostering trust and cooperation between medical and disability communities.
• Early consideration of these perspectives can help prevent social harms associated with the expanded use of WGS in the NICU.